-
Je něco špatně v tomto záznamu ?
The labeling of unsaturated γ-hydroxybutyric acid by heavy isotopes of hydrogen: iridium complex-mediated H/D exchange by C─H bond activation vs reduction by boro-deuterides/tritides
A. Marek, MH. Pedersen, SB. Vogensen, RP. Clausen, B. Frølund, T. Elbert,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
27593893
DOI
10.1002/jlcr.3432
Knihovny.cz E-zdroje
- MeSH
- alkeny chemie MeSH
- bor chemie MeSH
- deuterium chemie MeSH
- hydroxybutyráty chemie MeSH
- iridium chemie MeSH
- izotopové značení MeSH
- katalýza MeSH
- ligandy MeSH
- oxidace-redukce MeSH
- tritium chemie MeSH
- vodík-deuteriová výměna * MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
3-Hydroxycyclopent-1-ene-1-carboxylic acid (HOCPCA (1)) is a potent ligand for high-affinity γ-hydroxybutyric acid binding sites in the central nervous system. Various approaches to the introduction of a hydrogen label onto the HOCPCA skeleton are reported. The outcomes of the feasible C─H activation of olefin carbon (C-2) by iridium catalyst are compared with the reduction of the carbonyl group (C-3) by freshly prepared borodeuterides. The most efficient iridium catalysts proved to be Kerr bulky phosphine N-heterocyclic species providing outstanding deuterium enrichment (up to 91%) in a short period of time. The highest deuterium enrichment (>99%) was achieved through the reduction of ketone precursor 2 by lithium trimethoxyborodeuteride. Hence, analogical conditions were used for the tritiation experiment. [3 H]-HOCPCA selectively labeled on the position C-3 was synthetized with radiochemical purity >99%, an isolated yield of 637 mCi and specific activity = 28.9 Ci/mmol.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017066
- 003
- CZ-PrNML
- 005
- 20180516135639.0
- 007
- ta
- 008
- 180515s2016 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jlcr.3432 $2 doi
- 035 __
- $a (PubMed)27593893
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Marek, Aleš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, v.v.i., Flemingovo nám. 2, Prague 6, 16610, Czech Republic. marek@uochb.cas.cz. Center for Nuclear Technologies, DTU Nutech/Hevesy Laboratory, Technical University of Denmark, Frederiksborgvej 399, Building 202, Roskilde, 4000, Denmark. marek@uochb.cas.cz.
- 245 14
- $a The labeling of unsaturated γ-hydroxybutyric acid by heavy isotopes of hydrogen: iridium complex-mediated H/D exchange by C─H bond activation vs reduction by boro-deuterides/tritides / $c A. Marek, MH. Pedersen, SB. Vogensen, RP. Clausen, B. Frølund, T. Elbert,
- 520 9_
- $a 3-Hydroxycyclopent-1-ene-1-carboxylic acid (HOCPCA (1)) is a potent ligand for high-affinity γ-hydroxybutyric acid binding sites in the central nervous system. Various approaches to the introduction of a hydrogen label onto the HOCPCA skeleton are reported. The outcomes of the feasible C─H activation of olefin carbon (C-2) by iridium catalyst are compared with the reduction of the carbonyl group (C-3) by freshly prepared borodeuterides. The most efficient iridium catalysts proved to be Kerr bulky phosphine N-heterocyclic species providing outstanding deuterium enrichment (up to 91%) in a short period of time. The highest deuterium enrichment (>99%) was achieved through the reduction of ketone precursor 2 by lithium trimethoxyborodeuteride. Hence, analogical conditions were used for the tritiation experiment. [3 H]-HOCPCA selectively labeled on the position C-3 was synthetized with radiochemical purity >99%, an isolated yield of 637 mCi and specific activity = 28.9 Ci/mmol.
- 650 _2
- $a alkeny $x chemie $7 D000475
- 650 _2
- $a bor $x chemie $7 D001895
- 650 _2
- $a katalýza $7 D002384
- 650 _2
- $a deuterium $x chemie $7 D003903
- 650 12
- $a vodík-deuteriová výměna $7 D041961
- 650 _2
- $a hydroxybutyráty $x chemie $7 D006885
- 650 _2
- $a iridium $x chemie $7 D007495
- 650 _2
- $a izotopové značení $7 D007553
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a oxidace-redukce $7 D010084
- 650 _2
- $a tritium $x chemie $7 D014316
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pedersen, Martin H F $u Center for Nuclear Technologies, DTU Nutech/Hevesy Laboratory, Technical University of Denmark, Frederiksborgvej 399, Building 202, Roskilde, 4000, Denmark.
- 700 1_
- $a Vogensen, Stine B $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark.
- 700 1_
- $a Clausen, Rasmus P $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark.
- 700 1_
- $a Frølund, Bente $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark.
- 700 1_
- $a Elbert, Tomáš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, v.v.i., Flemingovo nám. 2, Prague 6, 16610, Czech Republic.
- 773 0_
- $w MED00002760 $t Journal of labelled compounds & radiopharmaceuticals $x 1099-1344 $g Roč. 59, č. 12 (2016), s. 476-483
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27593893 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180516135815 $b ABA008
- 999 __
- $a ok $b bmc $g 1300690 $s 1013906
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 59 $c 12 $d 476-483 $e 20160904 $i 1099-1344 $m Journal of labelled compounds & radiopharmaceuticals $n J Labelled Comp Radiopharm $x MED00002760
- LZP __
- $a Pubmed-20180515